Group One Trading’s Alzamend Neuro ALZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-954
Closed -$79K 6968
2023
Q4
$79K Buy
954
+890
+1,391% +$146K ﹤0.01% 4663
2023
Q3
$20.4K Sell
64
-10
-14% -$4.78K ﹤0.01% 5869
2023
Q2
$50.9K Buy
74
+39
+111% +$30.5K ﹤0.01% 5256
2023
Q1
$20.4K Sell
35
-31
-47% -$23.3K ﹤0.01% 5498
2022
Q4
$50.4K Sell
66
-69
-51% -$99.9K ﹤0.01% 4986
2022
Q3
$218K Buy
135
+98
+265% +$135K ﹤0.01% 4054
2022
Q2
$43K Sell
37
-52
-58% -$67.4K ﹤0.01% 5685
2022
Q1
$147K Sell
89
-2
-2% -$3.76K ﹤0.01% 5113
2021
Q4
$234K Buy
91
+64
+237% +$198K ﹤0.01% 4931
2021
Q3
$111K Buy
+27
New +$148K ﹤0.01% 5808

Other funds holding ALZN

Group One Trading's ALZN Position: Q3 2023 in Review

Group One Trading sold out of Alzamend Neuro (ALZN) in Q3 2023, closing a stake of 4 shares — an estimated $1.91K sold.

Group One Trading first reported a position in ALZN in Q3 2021 and held it in 7 quarters. The position peaked at $82K in Q4 2021. 22 funds tracked by Wall St. Rank hold ALZN as of Q3 2023.

  • Group One Trading reported no remaining Alzamend Neuro position as of Q3 2023 after selling out during the quarter.
  • Group One Trading sold 4 Alzamend Neuro shares in Q3 2023, an estimated $1.91K.
  • Group One Trading first reported a position in Alzamend Neuro in Q3 2021 and held it in 7 quarters.
  • Group One Trading's Alzamend Neuro position peaked at $82K in Q4 2021.
  • 22 funds tracked by Wall St. Rank held Alzamend Neuro as of Q3 2023.

Based on Group One Trading's 13F filing for Q3 2023, filed 9 Nov 2023.